Filtered By:
Therapy: Statin Therapy
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 11974 results found since Jan 2013.
Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer
CONCLUSION: Relugolix suppressed testosterone and was generally well tolerated when given with concomitant CV agents.TRIAL REGISTRATION: Clinical Trial ID NCT03085095.PRIOR PRESENTATION: Data presented at 15th Annual Genitourinary Cancers Symposium; February 17-19, 2022, San Francisco, CA, USA [Abstract 101, Poster board E11]. The published abstract from this presentation can be found at https://ascopubs.org/doi/10.1200/JCO.2022.40.6_suppl.101 .PMID:37713020 | DOI:10.1007/s12325-023-02634-7
Source: Adv Data - September 15, 2023 Category: Epidemiology Authors: Neal D Shore Bryan A Mehlhaff Michael S Cookson Daniel R Saltzstein Ronald Tutrone Bruce Brown Sophia Lu Mark Fallick Sarah Hanson Fred Saad Source Type: research
The influence of atorvastatin, amlodipine and ethoxidol on ubiquinol and ubiquinone endogenous plasma concentrations in patients with chronic heart failure
CONCLUSION: Amlodipine is able to neutralize the negative effect of atorvastin on the redox balance of CoQ10 in patients with CHF. An additional prescription of the antioxidant ethoxidol to standard therapy for patients with CHF was substantiated. Determination of the redox state of CoQ10 in plasma can be used to diagnose and assess the degree of oxidative stress in patients with cardiovascular diseases, as well as to assess the efficacy and safety of ongoing pharmacotherapy.PMID:37711113 | DOI:10.2174/1389200224666230913133201
Source: Current Drug Metabolism - September 15, 2023 Category: Drugs & Pharmacology Authors: Vladlena I Zozina Svetlana N Kondratenko Evgenia V Shikh Liudmila M Krasnykh Evgeny S Melnikov Vladimir G Kukes Source Type: research
Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer
CONCLUSION: Relugolix suppressed testosterone and was generally well tolerated when given with concomitant CV agents.TRIAL REGISTRATION: Clinical Trial ID NCT03085095.PRIOR PRESENTATION: Data presented at 15th Annual Genitourinary Cancers Symposium; February 17-19, 2022, San Francisco, CA, USA [Abstract 101, Poster board E11]. The published abstract from this presentation can be found at https://ascopubs.org/doi/10.1200/JCO.2022.40.6_suppl.101 .PMID:37713020 | DOI:10.1007/s12325-023-02634-7
Source: Adv Data - September 15, 2023 Category: Epidemiology Authors: Neal D Shore Bryan A Mehlhaff Michael S Cookson Daniel R Saltzstein Ronald Tutrone Bruce Brown Sophia Lu Mark Fallick Sarah Hanson Fred Saad Source Type: research
The influence of atorvastatin, amlodipine and ethoxidol on ubiquinol and ubiquinone endogenous plasma concentrations in patients with chronic heart failure
CONCLUSION: Amlodipine is able to neutralize the negative effect of atorvastin on the redox balance of CoQ10 in patients with CHF. An additional prescription of the antioxidant ethoxidol to standard therapy for patients with CHF was substantiated. Determination of the redox state of CoQ10 in plasma can be used to diagnose and assess the degree of oxidative stress in patients with cardiovascular diseases, as well as to assess the efficacy and safety of ongoing pharmacotherapy.PMID:37711113 | DOI:10.2174/1389200224666230913133201
Source: Current Drug Metabolism - September 15, 2023 Category: Drugs & Pharmacology Authors: Vladlena I Zozina Svetlana N Kondratenko Evgenia V Shikh Liudmila M Krasnykh Evgeny S Melnikov Vladimir G Kukes Source Type: research
Statin as repurposed drug in Ovarian Cancer: A comprehensive review
Curr Pharm Des. 2023 Sep 13. doi: 10.2174/1381612829666230913113808. Online ahead of print.ABSTRACTWith a prevalence rate of 6.6 per 100,000 women, ovarian cancer is the third most lethal gynecological tumor in the world. Several factors like family history, nulliparity, late menopause, genetic mutation, and an unhealthy lifestyle contribute to increasing the risk of ovarian cancer development. Novel research studies suggest that ovarian cancer may be caused by changes in the lipid metabolic profile that trigger inflammatory responses. Moreover, ovarian cancer patients will eventually experience chemoresistance. Statin, a ...
Source: Current Pharmaceutical Design - September 15, 2023 Category: Drugs & Pharmacology Authors: Asmara Ahmad Sadia Javed Shumaila Kiran Source Type: research
2023 Chinese guideline for lipid management
Front Pharmacol. 2023 Aug 29;14:1190934. doi: 10.3389/fphar.2023.1190934. eCollection 2023.ABSTRACTAtherosclerotic cardiovascular disease (ASCVD) is the leading cause of death among urban and rural residents in China, and elevated low-density lipoprotein cholesterol (LDL-C) is a risk factor for ASCVD. Considering the increasing burden of ASCVD, lipid management is of the utmost importance. In recent years, research on blood lipids has made breakthroughs around the world, hence a revision of Chinese guideline for lipid management is imperative, especially since the target lipid levels in the general population vary in respe...
Source: Atherosclerosis - September 15, 2023 Category: Cardiology Authors: Jian-Jun Li Shui-Ping Zhao Dong Zhao Guo-Ping Lu Dao-Quan Peng Jing Liu Zhen-Yue Chen Yuan-Lin Guo Na-Qiong Wu Sheng-Kai Yan Zeng-Wu Wang Run-Lin Gao Source Type: research
The influence of atorvastatin, amlodipine and ethoxidol on ubiquinol and ubiquinone endogenous plasma concentrations in patients with chronic heart failure
CONCLUSION: Amlodipine is able to neutralize the negative effect of atorvastin on the redox balance of CoQ10 in patients with CHF. An additional prescription of the antioxidant ethoxidol to standard therapy for patients with CHF was substantiated. Determination of the redox state of CoQ10 in plasma can be used to diagnose and assess the degree of oxidative stress in patients with cardiovascular diseases, as well as to assess the efficacy and safety of ongoing pharmacotherapy.PMID:37711113 | DOI:10.2174/1389200224666230913133201
Source: Current Drug Metabolism - September 15, 2023 Category: Drugs & Pharmacology Authors: Vladlena I Zozina Svetlana N Kondratenko Evgenia V Shikh Liudmila M Krasnykh Evgeny S Melnikov Vladimir G Kukes Source Type: research
Statin as repurposed drug in Ovarian Cancer: A comprehensive review
Curr Pharm Des. 2023 Sep 13. doi: 10.2174/1381612829666230913113808. Online ahead of print.ABSTRACTWith a prevalence rate of 6.6 per 100,000 women, ovarian cancer is the third most lethal gynecological tumor in the world. Several factors like family history, nulliparity, late menopause, genetic mutation, and an unhealthy lifestyle contribute to increasing the risk of ovarian cancer development. Novel research studies suggest that ovarian cancer may be caused by changes in the lipid metabolic profile that trigger inflammatory responses. Moreover, ovarian cancer patients will eventually experience chemoresistance. Statin, a ...
Source: Current Pharmaceutical Design - September 15, 2023 Category: Drugs & Pharmacology Authors: Asmara Ahmad Sadia Javed Shumaila Kiran Source Type: research
The influence of atorvastatin, amlodipine and ethoxidol on ubiquinol and ubiquinone endogenous plasma concentrations in patients with chronic heart failure
CONCLUSION: Amlodipine is able to neutralize the negative effect of atorvastin on the redox balance of CoQ10 in patients with CHF. An additional prescription of the antioxidant ethoxidol to standard therapy for patients with CHF was substantiated. Determination of the redox state of CoQ10 in plasma can be used to diagnose and assess the degree of oxidative stress in patients with cardiovascular diseases, as well as to assess the efficacy and safety of ongoing pharmacotherapy.PMID:37711113 | DOI:10.2174/1389200224666230913133201
Source: Current Drug Metabolism - September 15, 2023 Category: Drugs & Pharmacology Authors: Vladlena I Zozina Svetlana N Kondratenko Evgenia V Shikh Liudmila M Krasnykh Evgeny S Melnikov Vladimir G Kukes Source Type: research
Statin as repurposed drug in Ovarian Cancer: A comprehensive review
Curr Pharm Des. 2023 Sep 13. doi: 10.2174/1381612829666230913113808. Online ahead of print.ABSTRACTWith a prevalence rate of 6.6 per 100,000 women, ovarian cancer is the third most lethal gynecological tumor in the world. Several factors like family history, nulliparity, late menopause, genetic mutation, and an unhealthy lifestyle contribute to increasing the risk of ovarian cancer development. Novel research studies suggest that ovarian cancer may be caused by changes in the lipid metabolic profile that trigger inflammatory responses. Moreover, ovarian cancer patients will eventually experience chemoresistance. Statin, a ...
Source: Current Pharmaceutical Design - September 15, 2023 Category: Drugs & Pharmacology Authors: Asmara Ahmad Sadia Javed Shumaila Kiran Source Type: research
The influence of atorvastatin, amlodipine and ethoxidol on ubiquinol and ubiquinone endogenous plasma concentrations in patients with chronic heart failure
CONCLUSION: Amlodipine is able to neutralize the negative effect of atorvastin on the redox balance of CoQ10 in patients with CHF. An additional prescription of the antioxidant ethoxidol to standard therapy for patients with CHF was substantiated. Determination of the redox state of CoQ10 in plasma can be used to diagnose and assess the degree of oxidative stress in patients with cardiovascular diseases, as well as to assess the efficacy and safety of ongoing pharmacotherapy.PMID:37711113 | DOI:10.2174/1389200224666230913133201
Source: Current Drug Metabolism - September 15, 2023 Category: Drugs & Pharmacology Authors: Vladlena I Zozina Svetlana N Kondratenko Evgenia V Shikh Liudmila M Krasnykh Evgeny S Melnikov Vladimir G Kukes Source Type: research
Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association
The objective of this scientific statement is to evaluate contemporary evidence that either supports or refutes the conclusion that aggressive low-density lipoprotein cholesterol lowering or lipid lowering exerts toxic effects on the brain, leading to cognitive impairment or dementia or hemorrhagic stroke. The writing group used literature reviews, references to published clinical and epidemiology studies, clinical and public health guidelines, authoritative statements, and expert opinion to summarize existing evidence and to identify gaps in current knowledge. Although some retrospective, case control, and prospective lon...
Source: Arteriosclerosis, Thrombosis and Vascular Biology - September 14, 2023 Category: Cardiology Authors: Larry B Goldstein Peter P Toth Jennifer L Dearborn-Tomazos Robert P Giugliano Benjamin J Hirsh Jessica M Pe ña Magdy H Selim Daniel Woo American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Source Type: research
New Targets in Atherosclerosis: Vascular Smooth Muscle Cell Plasticity and Macrophage Polarity
Clin Ther. 2023 Sep 12:S0149-2918(23)00319-3. doi: 10.1016/j.clinthera.2023.08.015. Online ahead of print.ABSTRACTPURPOSE: Despite an increase in treatment options, and substantial reductions in cardiovascular mortality over the past half-century, atherosclerosis remains the most prevalent cause of premature mortality worldwide. The development of innovative new therapies is crucial to further minimize atherosclerosis-related deaths. The diverse array of cell phenotypes derived from vascular smooth muscle cells (SMCs) and macrophages within atherosclerotic plaques are increasingly becoming recognized for their beneficial a...
Source: Atherosclerosis - September 14, 2023 Category: Cardiology Authors: Michael Hutton Madeleine Frazer Alexander Lin Sanjay Patel Ashish Misra Source Type: research
Early Computed Tomography Coronary Angiography and Preventative Treatment in Patients with Suspected Acute Coronary Syndrome A secondary analysis of the RAPID-CTCA trial
CONCLUSIONS: Prescription patterns of preventative treatment varied during index hospitalisation in patients with suspected acute coronary syndrome. Early CTCA facilitated targeted individualisation of these therapies based on the extent of coronary artery disease.PMID:37709109 | DOI:10.1016/j.ahj.2023.09.003
Source: Atherosclerosis - September 14, 2023 Category: Cardiology Authors: Kang-Ling Wang Mohammed N Meah Anda Bularga Katherine Oatey Rachel O'Brien Jason E Smith Nick Curzen Attila Kardos Liza Keating Dirk Felmeden Robert F Storey Steve Goodacre Carl Roobottom David E Newby Alasdair J Gray RAPID-CTCA Investigators Source Type: research
